Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
about
Beyond BRAF: where next for melanoma therapy?Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotypeCIViC databaseCombined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeNegative feedback regulation of the ERK1/2 MAPK pathwayCombinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.MERTK receptor tyrosine kinase is a therapeutic target in melanoma.Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.Novel somatic mutations to PI3K pathway genes in metastatic melanomaThe MAPK pathway across different malignancies: a new perspective.Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.Genotyping of cutaneous melanoma.Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profilingDevelopment of organometallic S6K1 inhibitors.Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaThe broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice.Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma.Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.Targeting drivers of melanoma with synthetic small molecules and phytochemicals.Epithelial to mesenchymal transition is associated with rapamycin resistanceA novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signalingFisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cellsDiverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorCRAF R391W is a melanoma driver oncogeneTherapeutic implications of melanoma heterogeneity.Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.Combination therapies for the treatment of advanced melanoma: a review of current evidence.Resistance to RAF inhibitors revisited.
P2860
Q54903526-A59E1259-F7AD-4857-8620-F2EF94DCF7FCQ54903541-DF5820A4-C959-4067-A220-1A6572284E89Q54903549-0769C158-D798-4A16-B295-0587F9988529Q54903550-A81582E6-1E53-49EC-80AE-F7BFAEF223EEQ54903553-61DA6914-7C82-4AFD-A00C-5A039D4F5282Q54903562-769D105F-9035-4E6B-B246-D7D8DA6130C8Q54903563-6D271710-178F-473C-ADCA-205122721FBFQ54903574-EC2634F2-5551-4B58-B15D-D5737B161CD6Q95984236-5D6F1B1D-1518-4F27-A5CA-4F4721BBE51CQ95984239-F8E07C7B-797E-4BFB-A855-02594D905443Q95984241-50DA7C40-D6A5-44E9-919B-DB1615075871Q95984249-E60F120E-092C-46EC-86E7-FF78D6485283
P1343
Q27006853-57069799-FE6D-4DF9-93DE-15209CEADCD7Q27334924-46A30C93-B08B-44F0-AE16-46808F0103B3Q27612411-B82A690C-022A-4CF5-AE3C-608F4A12F0C8Q27852093-CEDE9F36-8F1E-4863-B452-8FE8BB6636DAQ27852994-09C23FCE-C705-497D-938B-1AE1CDD4E218Q27853104-8318DF13-0B0C-4E6F-9E93-93087F0FBAF9Q27853295-18BA5C16-AB2D-4062-8A8A-2CDEBB1E4882Q28079202-CDFB10D3-AE47-4A39-B256-522F570DE99EQ30277902-A69A718F-10BB-46EB-93E6-C5BDC6A830B8Q30539324-8E724290-8630-4529-8045-D44590DEFCFEQ33570005-324BF2A2-5C09-47B5-97F0-29C78E10B9B2Q33688428-2AD071DE-8527-463F-892E-0CE99CBA0D7EQ33808166-DD098FB8-0D01-470D-85DC-BF0736E8C5D3Q34253185-21B781F9-64D6-4170-8D9C-B5D01C808507Q34389570-182D5C55-391B-4973-AD09-54CD75C1F4DDQ34459097-AF9D85F2-D274-42E9-A9FC-E7566CE6E2AFQ34661815-955D6671-1A53-421D-B044-1747FB570102Q34667738-88B998E0-1112-45DD-BA83-D82127B8F816Q34737562-F90A56A9-B5E0-4299-8B1F-AF1E8992F758Q34891733-F8935B6A-D1A1-4617-BDAE-E6ECF7687FF2Q35408594-0EC1978F-30FC-4E38-AE19-F7177D11D956Q35597799-126F012C-578C-4EE0-BF17-895C04B796EEQ35606746-ADF8EB72-B506-40C9-AF24-9088132928F6Q35609071-54616103-7409-4847-B0B0-E08FCA5FB93FQ35746524-7D85EF39-4776-4FD5-B3EB-849FCED034A1Q35775241-A4A9BBDD-018F-438B-9E3F-B57B0AA72591Q36054290-C491F149-FFB9-45A0-B04D-188EF25F81E6Q36141097-3965FAAA-D4DF-428F-837C-8B78744CC49CQ36260570-D09545FD-3A1C-4A88-80F5-ECB8A468B4A2Q36384334-52C91792-4BED-4926-B9D0-C228CEB8F7D6Q36414039-E67FA487-FA45-43C7-A2D6-382CFA970C39Q36605057-237DD0F9-0559-45AD-B00B-E1E377E90334Q36929804-107BBD51-C276-49E5-82DB-AE19607E89D0Q36980239-C2D19498-D73D-477C-93BD-BDF0D3985061Q37149871-8D80BEBB-6108-476A-B995-D364B402AED0Q37462300-25E93D3C-4DF9-4771-837A-3D08C32E8D76Q37496876-4B1739F8-7A3A-4CF9-A8A7-4882B92E8D1DQ37619716-F4B04FD6-473F-46F8-812B-C47F01697B12Q37621608-E54619F4-E888-4457-99F8-C0386F64A3FBQ37625751-6AFDEBB6-70A3-4B87-BC83-5681C574849B
P2860
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Reversing melanoma cross-resis ...... argeting the AKT/mTOR pathway.
@ast
Reversing melanoma cross-resis ...... argeting the AKT/mTOR pathway.
@en
Reversing melanoma cross-resis ...... argeting the AKT/mTOR pathway.
@nl
type
label
Reversing melanoma cross-resis ...... argeting the AKT/mTOR pathway.
@ast
Reversing melanoma cross-resis ...... argeting the AKT/mTOR pathway.
@en
Reversing melanoma cross-resis ...... argeting the AKT/mTOR pathway.
@nl
altLabel
Reversing Melanoma Cross-Resis ...... Targeting the AKT/mTOR Pathway
@en
prefLabel
Reversing melanoma cross-resis ...... argeting the AKT/mTOR pathway.
@ast
Reversing melanoma cross-resis ...... argeting the AKT/mTOR pathway.
@en
Reversing melanoma cross-resis ...... argeting the AKT/mTOR pathway.
@nl
P2093
P2860
P50
P3181
P1433
P1476
Reversing melanoma cross-resis ...... argeting the AKT/mTOR pathway.
@en
P2093
Begonya Comin-Anduix
Charles Ng
Connie Chu
Deliang Guo
John A Glaspy
Mohammad Atefi
Narsis Attar
Paul S Mischel
Ramin Nazarian
Roger S Lo
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0028973
P407
P577
2011-01-01T00:00:00Z